SunTrust analyst Edward Nash lowered his price target on Spark Therapeutics (ONCE) to $61, saying the company's SPK-8011 update has dimmed the outlook for its hemA program. Nash notes that while the FVIII activity reached the 30% threshold set by his physician consultants, it is below that of BioMarin (BMRN) BMN-270, adding the immune risk cannot be eliminated from the treatment. The analyst keeps his Buy rating on Spark Therapeutics, citing expectations of a gradual uptake of its Luxturna in 2018 with modeled commercial opportunity of $322M. Nash adds that Luxturna's commercial success should deepen the company's understanding of hemophilia and help differentiate its products from competitors.